Format

Send to

Choose Destination
See comment in PubMed Commons below
J Med Chem. 2011 Mar 24;54(6):1715-23. doi: 10.1021/jm101354u. Epub 2011 Feb 22.

14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment.

Author information

1
Threshold Pharmaceuticals , 1300 Seaport Blvd, Suite 500, Redwood City, California 94063, United States. jduan@thresholdpharm.com

Abstract

14-Aminocamptothecins were synthesized in good yields by treating camptothecin (1a) and 7-ethylcamptothecin (1b) with 90% fuming nitric acid either neat or in acetic anhydride and then followed by reduction of the resulting 14-nitrocamptothecins (2). 14-Aminocamptothecin (3a) and 7-ethyl-14-aminocamptothecin (3b) demonstrated excellent cytotoxic potency against human tumor cell lines in vitro, and they are not substrates for any of the major clinically relevant efflux pumps (MDR1, MRP1, and BCRP). 3a and 3b showed similar cytotoxicity against human and mouse bone marrow progenitor cells. This is in contrast to many camptothecin analogues, which are substrates for efflux pumps and are dramatically more toxic to human marrow cells relative to murine. 3a and 3b demonstrated significant brain penetration when dosed orally in mice. 3b showed significantly better efficacy relative to topotecan when dosed orally in the three ectopic xenograft models, H460, HT29, and PC-3. On the basis of its favorable in vitro and in vivo profile, 3b warrants future development.

PMID:
21341674
DOI:
10.1021/jm101354u
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Chemical Society
    Loading ...
    Support Center